Introduction

CSC Concept
leukemia-initiating cells (cluster of differentiation (CD)34 + CD38) and breast cancer-initiating cells (CD44 + CD24
-/lo ) and provided scientific basis for the CSC hypothesis. (7) (8) (9) Development of drug resistance and disease recurrence and metastasis could naturally be the consequences of tumor heterogeneity and plasticity. The latter characteristics also could result in cells having distinct characteristics, including sensitivity to therapy. (10) The hypothesis that tumors arise via sequential mutation and clonal selection has been proposed to be incompatible with a CSC model. In fact, studies such as that of Jan, et al., have provided compelling evidence that both models are correct. (11) Although mutations may occur in any cell, those that occur in non-self-renewing cell populations are extinguished through cellular senescence. CSC mutation may lead to these selective population clonal growth, causing further mutation, and keep continue to mutate and evolve even after full transformation. Thus, cancers may contain multiple CSC clones. (12) Until now, evidence for the existence of CSC has been controversial, but the hypothesis is extremely attractive because it provides a conceptual framework on which new therapeutic approaches could be built, and is any drug capable of killing CSCs would, in theory, be curative. Now, three independent studies of mouse models of brain (13) , skin (14) and intestinal (15) tumors provide the first evidence that CSC do exist and arise de novo during tumor formation in intact organs. (16) Over the last ten years, the notion that tumors are maintained by their own stem cells, has created great excitement in the research community. (17) on the genetic and biochemical mechanisms which cause drug resistance. Nonetheless, cancer is widely understood as a heterogeneous disease and there is increasing awareness that intratumoral heterogeneity contributes to therapy failure and disease progression.(3) A tumor is not simply a bag of homogeneous malignant cells. Instead, a tumor is a complex ecosystem containing tumor cells, as well as various infiltrating endothelial, hematopoietic, stromal and other cell types which can influence the function of tumor as a whole. (18) Many leukimias and solid tumors were defined by their pehotypic and functional heterogeneity features, including genetic mutations, epigenetic changes, microenvironment interactions, and if a cellular hierarchy was present or absent. Different cellular mechanisms have been postulated to account for intratumoral heterogeneity. (19) It is now commonly accepted that inherited mutations and environmental carcinogens can lead to the development of premalignant clones ( Figure 1 ). (12) After further mutations, one cell reaches a critical state which confers a survival or growth advantage over the normal cells. Such cells have the ability to initiate a malignant tumor. They share plenty features of normal stem cells, including the capacity for self-renewal and differentiation, and are widely termed CSC. (20) Central to CSC concept is the observation that not all cells in tumors are equal. The CSC concept presupposes that, similar to the growth of normal proliferative tissues such as bone marrow, skin or intestinal epithelium, the growth of tumors is fueled by limited numbers of dedicated stem cells which are capable of self-renewal. (17) Both CSCs and normal tissue stem cells possess self-renewal capability, however, self-renewal is typically deregulated in CSC. For many cancers, CSC represent a distinct population that can be prospectively isolated from the remainder of the tumor cells and can be shown to have clonal long-term repopulation and self-renewal capacity, the defining features of a CSC. (21, 22) Despite the advances in cancer treatment, many patients still fail therapy, resulting in disease progression, recurrence and reduced overall survival. Historically, much focus has been The CSC hypothesis explains that there exists, within a tumor, a minority cell type which has the characteristics of stem cells, these cells can self-renew and can differentiate to form all of the cell types that constitute the original tumor from a small number of cells.(21) It seems clear that, at least in hematopoetic (23) and some solid tumors including pancreatic (24) , prostate (25) , colon (17, 26, 27) , breast (28, 29) , lung (30) , and brain (31, 32) , a small subset of cells can be isolated which can self-renew and form welldifferentiated tumors similar to that of the patient's tumor from which they arise. However, the CSC hypothesis may not be true for all tumor types or for all of these cells all of the time. (33) (34) (35) (36) In reality, it has been suggested that stemness may be a dynamic state, which is a function of the cell's interaction with the environment. (37) The CSC model states that tumors are organized hierarchically with a subset of tumor cells at their apex, which possess self-renewal and multilineage differentiation potential. (21, 38) This model therefore suggests that tumors are organized in a similar, albeit distorted, mannered as are their tissues of origin, and could potentially explain several phenomena that are currently incompletely understood. (39) According to the CSC model, minimal residual disease and tumor recurrence after treatment would be a result from remaining therapy-resistant CSC fraction, whereas metastatic potential would be a CSC-specific property. Although these hypotheses are appealing, they lack conclusive experimental evidence. (40) The definition of CSCs as the only self-renewing tumor cells that capable of seeding a new tumor implies that CSCs are also responsible for initiation of metastases, a notion strengthened by the connection between CSCs and epithelial-mesenchymal transition (EMT) (41) (42) (43) (44) which is associated with metastatic behavior and poor prognosis (45) . Transient and long-term quiescence, the latter also termed dormancy, are generally believed to be fundamental attributes of adult stem cells. (46, 47) On the basis of this premise, stem cells are often identified by their propensity to retain DNA labels much longer than their rapidly proliferating offspring. Dormancy may be a crucial mechanism for the resistance of CSCs to anti-proliferative chemotherapy. Besides, if indeed CSC occur in a dormant state, this would explain the appearance of local recurrence or distant metastasis after long lag periods. (17) It is often proposed that CSCs are resistant to therapy in the similar way that normal stem cells are protected against insult. These protections include, for example, mechanisms such as quiescence, expression of ATPbinding cassette (ABC) drug pumps, high expression of antiapoptotic proteins and resistance to DNA damage.
(48) Some groups have started to explore if CSCs are indeed more resistant to therapy than their progeny. For instance, CD133-expressing glioma cells survive ionizing radiation better relative to CD133-tumor cells.(49) CD44 hi CD24lo breast cancer CSCs appear intrinsically resistant to conventional chemotherapy (50) and ionizing radiation (51) . Meanwhile chronic myeloid leukemia (CML) is sustained by leukemic stem cells that are relatively resistant to the drug Imatinib. (52, 53) Nevertheless, the phenomenon of intrinsically therapy-resistant CSCs cannot be generalized, as for instance, the undifferentiated cells which drive testicular germ cell tumors are more sensitive to radiation or cisplatin therapy than their differentiated cellular progeny. (54) Tumor cells that escape therapy, however, may not be endowed with intrinsic therapy resistance. Rather, they may simply be the stochastic winners of the tumor cell-killing process. On the opposite, when intrinsic differences in the sensitivity of cancer cells to therapy do exist, these may also be determined genetically rather than by epigenetic differences. (55) CSCs must be defined functionally by well-validated assays such as in vivo transplantation instead on the basis of immunophenotype alone. Nevertheless, a number of markers have proven useful for the isolation of subsets enriched for CSCs in multiple types of solid tumors, including CD133, CD44, epithelial cell adhesion molecule (EpCAM), and aldehyde dehydrogenase (ALDH) activity. In the case of human leukemia, a combination of CD34, CD38, and interleukin (IL)-3 receptor subunit alpha (IL3Ra) has enabled the prospective isolation of leukemia stem cells. It should be noted that none of these markers are exclusively expressed by CSCs. (19) The search for more robust markers of CSCs in glioblastoma and other brain tumors has revealed stagespecific embryonic antigen 1 (SSEA-1)/CD15/Lewis X and a6-integrin. SSEA-1 was identified as a CSC marker in both human glioblastoma and syngeneic mouse models of medulloblastoma.(56-58) Despite a high proportion of specimens lacking CD133 + cells, SSEA-1 enriched for CSCs by 100-fold in almost every human glioblastoma tumor evaluated. (57) In another approach, the perivascular microenvironment in which brain CSCs reside and identified a6-integrin as a CSC marker that was required for maintenance of CSCs in vivo has been examined. (59) Co-expression of CD133 and a6-integrin was observed in some but not all tumors. The genetic mutation profile may also influence the nature and phenotype of CSCs, as suggested by studies on different genetic mouse models of lung adenocarcinoma (60) , whereas epigenetic changes in regulatory genes could impact marker expression itself. (64) . In ovarian cancers, strikingly little concordance was found between CD133 and reported ovarian CSC markers including CD117, CD44, and ALDH1 activity (65, 66) , most probably explained by many groups relying on cultured cells as opposed to freshly sorted tumors. Finally, in patients with non-small cell lung cancer, even though CD133, CD44, and EpCAM proved ineffective for the isolation of CSC, CD166 showed as a robust marker in more than 50% of cases. (67) Nevertheless, a combination of markers can refine the CSC phenotype. (19) Mutations directly influence the stemness and EMT qualities, whereas differentiation and reversion to the CSC state affect the potential of these mutations to be passed on to progeny. The addition of microenvironmental cues to this model discloses a system that is constantly being fine-tuned to provide an optimal tumor-supporting setting.(40) From a cell biological perspective, the link between EMT, migratory CSCs and metastatic potential is intriguing, but further molecular insight is needed to fully understand and prove these connections. The observation that EMT regulators, such as Snail and zinc-finger-E-box-binding (Zeb)1, can be switched on and off in tumors as a result of a molecular circuitry that involves micro-RNA-dependent regulation provides a starting point. (68) (69) (70) Identifying the cues that control the activity of this network will further elucidate the process and will likely also provide targets which can modulate metastasis and interfere with CSC qualities.
From a clinical perspective, our understanding of the interactions between CSCs, differentiated tumor cells and the microenvironment is of utmost importance. As CSCs have been suggested to selectively resist therapy, these interactions are not only important to understand treatment outcome, but could also provide useful targets for therapy. (39, 71) Based on this, the next ten years will transform CSCs from an intensely debated concept to a better understood and actively targeted tumor property.
The cell of origin for CSC is a fundamental question in the field that remains unanswered at this time. A common notion is that normal pluripotent stem and/or progenitor cells may be the cell of origin for CSC because these two cell types possess similar hallmark functional characteristics, namely, self-renewal and differentiation. However, there is a lack of experimental evidence to provide insight into the molecular mechanisms required to reprogram normal pluripotent cells into CSC. The most logical and straightforward hypothesis is that accumulation of genetic alterations may trigger the transformation of normal pluripotent cells into CSC. It is unclear whether a distinct set and/or a threshold number of genetic alterations are needed to drive the transition of normal pluripotent cells into CSC. (72) Emerging literature is revealing bidirectional plasticity between the non-CSC and CSC populations to support non-CSCs as the cell of origin for CSCs. Several groups reported that non-CSCs can be induced to dedifferentiate into CSCs by co-opting oncogenic pathways and/or through interaction with the microenvironment. A recent study showed that hyperactive kirsten rat sarcoma viral oncogene (KRAS) and Wnt signaling cooperate to dedifferentiate villus cells into intestinal CSC in a nuclear factor-kappaB (NF-kB) dependent fashion. (73) Similarly, KRAS functioned in concert with another oncogene, cellular myelocytomatosis oncogene (Myc), to promote the conversion of differentiated mouse fibroblasts into CSC.(74) Mammary non-CSC epithelial cells were shown to spontaneously dedifferentiate to CSC in vitro and in vivo. (35) . In addition, the conversion rate of non-CSC to CSC was more pronounced in vivo, suggesting that the tumor microenvironment may play a critical role in CSC expansion. (35) .
The available data suggest that cancer progresses through multistep processes involving both genetic mutations and epigenetic abnormalities. However, it still remains unclear how epigenetic abnormality occurs during cancer development. Previous studies have demonstrated that cancer-promoting inflammatory stimuli induce drastic changes in DNA methylation patterns.(75) These results suggest that external signals could be a cause of epigenetic abnormalities in cancer cells. In contrast, large-scale sequencing projects have identified a number of mutations of epigenetic regulator genes across a wide variety of cancer types. (76) These results clearly demonstrate that some of the epigenetic abnormalities observed in cancers are attributable to genetic mutations and highlight the primary Origin of CSC role of genetic mutations, even against a background of epigenetic alterations (Figure 2) . (77) Induced pluripotent stem cell (iPSC) derivation processes share many characteristics with cancer development where during reprogramming, somatic differentiated cells will show unlimited proliferation for self-renewal and global alterations for transcriptional program, similar to carcinogenesis critical events. (78) The metabolic switch to glycolysis that occurs during somatic cell reprogramming is similarly observed in cancer development. (79) Such similarities suggest that reprogramming processes and cancer development may be partly promoted by overlapping mechanisms.(80) Practically, the forced induction of the critical reprogramming factor organic cation transporter (Oct)-3/4 in adult somatic cells results in dysplastic growth in epithelial tissues through the inhibition of cellular differentiation in a manner which is similar to that in embryonic cells. (81) These studies provided a possible link between transcription-factor-mediated reprogramming and cancer development. (82) Remarkably, the process of dedifferentiation or reprogramming of the somatic cells by Yamanaka factors, many of which are oncogenes, offers a new insight into CSC. These may be the somatic cells dedifferentiation product after oncogenic insult. Cancer cells have an amazing rate of survival. They can even exploit and subvert the cellular machinery by proliferation, dedifferentiation, and even transdifferentiation, to achieve that goal. (83) There are many parallels between reprogramming and cancer. The similarities between the process of reprogramming cells to iPCS and differentiated tumor cells to CSC propose that some of these mechanisms, like epigenetic resetting, can render cells in a susceptible condition where genetic alterations are only the next step toward transformation and tumor progression. Knowing the mechanisms governing cellular reprogramming and induced pluripotency may shed light into deciphering the processes involved in tumorigenesis. (83) (104) EMT is required for primary carcinoma to invade and disseminate, because these pioneer invasive cells have important features (mesenchymal and a stem celllike phenotype) which can initiate a differentiated epitheliallike structure. A reversion process of this differentiated phenotype through a process of MET is important for macrometastasis formation and next forming a bulk of the secondary tumor mass. This hypothesis was formulated earlier from an analysis of the progression of colon primary tumors and liver metastases, where it was proposed that CSC could acquire a mesenchymal phenotype, and thereby become migratory CSC that will form metastasis. (44) Consistent with the reversible nature of EMT, differentiated cancer cells can do a transition into CSC, and vice versa, enabling oncogenic mutations which arose in differentiated cancer cells to integrate through EMT into CSC as EMT promotes cell invasion that leads to tumor cell dissemination, this procedure enables CSC with new oncogenic mutations to clonally expand, following invasion, dissemination and MET in secondary tumors. (44, 105) In cancer, both EMT and CSC generation have been associated with transforming growth factor (TGF)-β signaling. For example, breast cancer CSCs show higher levels of TGF-β1 and type II TGF-β1 receptor expression than the more differentiated cells, and inhibition of TGF-β signaling in CSCs re-establishes an epithelial phenotype. (110) , and the inhibition of Notch signaling suppresses EMT and CSCs in a xenograft model (111) .
Regulating the activity of E-cadherin repressors may seem an obvious strategy to combat cancer progression. However, these inducers of the full EMT program are EMT direct lineage conversion, emphasizing the link between reprogramming and oncogenesis. (88, 89) The convergence and commonality of CSC and iPSC opens a new avenue to develop therapeutic approaches to fight recurring cancers. transcription factors, and are very difficult to target. RNA interference provides some hope in terms of specificity, but further development is indeed needed to increase the stability of these reagents and the efficiency in cell targeting and intracellular delivery.(91) Small-molecule inhibitors or antibodies directed against the epidermal growth factor receptor (EGFR), insulin-like growth factor receptor (IGFR), platelet-derived growth factor receptor (PDGFR), hepatocyte growth factor receptor (HGFR), TGF-β receptor (TGFβR), and endothelin type A receptor (ETAR) have been effective in preclinical and clinical trials. Although initially developed as inhibitors of cell proliferation or angiogenesis, it is likely that these molecules interfere with EMT.(112) For instance, Cetuximab or Panitumumab, two antibodies against EGFR, or Erlotinib and Gefitinib, two small molecules that act as competitive inhibitors of the EGFR kinase, are currently used clinically to treat advanced carcinoma. Nevertheles, studies in cell lines show that not all cells expressing high levels of EGFR respond to Erlotinib or Gefitinib. Interestingly, there is an obvious correlation between the EMT status of each cell line and the degree of response.(113-115) Another approach to overcome refractoriness is to target directly the CSC. Lately, salinomycin was identified from a library consisting of 16,000 small molecules for its selective cytotoxity toward enriched breast CSC. This pioneer study provides a proof of principle that CSC exhibiting EMT features can be selectively targeted by drugs. (116) The CSC Nische CSCs are tumor cells which have the principal properties of self-renewal, clonal tumor initiation capacity, and clonal long-term repopulation potential. (21, 22) They also display plasticity by reversibly transitioning between stem and non-stem cell states. CSCs have the capability to evade cell death and metastasize, although they may stay dormant for long periods of time.(117) Both experimental models and clinical studies indicate that CSCs survive many commonly employed cancer therapeutics. (18) As is the case for normal stem cells, CSCs are believed to reside in niches. Niches are specialized microenvironments which regulate adult stem cell fate by providing cues in form of both cell-cell contacts and secreted factors. (Figure 3) . (122) Metastasis happened when disseminated cancer cells, away from the primary site, recreate a full-fledged tumor in another tissues. How the cancer cells can move from a tumor to a distant organ via circulation is still become the interest of cancer biologist and clinical oncologist. The latest findings have started to define the sources, phenotypic properties, hosting niches, and signaling pathways which support the survival, self-renewal, dormancy and reactivation of cancer cells that initiate metastasis, that is metastatic stem cells. (123) Metastatic growth in distant organs is the major reason of cancer mortality. The development of metastasis is a multistage process with several rate-limiting steps. (124) Even though dissemination of tumor cells seems to be an early and frequent event (125) , the successful initiation of metastatic growth, a process termed metastatic colonization, is not efficient for many cancer types and is accomplished only by a minority of cancer cells that reach distant sites (126, 127) . Prevalent target sites are characteristic of many tumor entities (128) , proposing that inadequate support by distant tissues contributes to the inefficiency of metastatic process. Small population of CSC is critical for metastatic colonization, that is, the initial expansion of cancer cells at the secondary site, and that stromal niche signals are vital to this expansion process (Figure 4) . (122) A component of the ECM, called Periostin (POSTN), is expressed by fibroblasts in normal tissue and in stroma of the primary tumor. Infiltrating tumor cells have to induce stromal POSTN expression in the secondary target organ (in this case lung) to initiate colonization. POSTN is required to allow CSC maintenance, and blocking its function avoids metastasis. POSTN recruits Wnt ligands and thereby increases Wnt signaling in CSC. The education of stromal cells by infiltrating tumor cells is an crucial step in metastatic colonization and that preventing de novo niche formation may be a novel strategy for the treatment of metastatic disease. (129) Organs are composed of the cells which perform the main organ function (e.g., secrete hormones or enzymes) and the stroma (from Latin or Greek, often translated as mat or bed), the supportive framework of an organ. The stroma can be divided into several classes, there are the ECM, which is composed of proteoglycans, hyaluronic acid and fibrous proteins (e.g., collagen, fibronectin, and laminin), and stromal cells. The stromal cells include mesenchymal supporting cells (e.g., fibroblasts and adipocytes), cells of the vascular system, and cells of the immune system. Various peptide factors (e.g., growth factors, chemokines, cytokines, antibodies) and metabolites are also found in the stroma. The stroma is essential for normal organ development. (130-132) Different components of tumor stroma similarly affect the progression of the tumor. As tumors develop and progress, they undergo dramatic morphological changes (133, 134) , which also involves the stroma (133, (135) (136) (137) . The importance of stage-specific changes of the stroma is not yet completely comprehensible. However, in most cases the stroma of the later stages is more supportive of tumor progression than the stroma of early stages. (138) Just as normal developing organs, such as liver and kidneys, have systemic consequences for the organism, so does tumor organ. The dramatic systemic effects of the tumor organ are not limited to metastatic spread, but also include effects on immunity, coagulation and metabolism. Certainly it is these major systemic changes which cause the majority of cancer deaths, rather than effects of the direct overgrowth of the primary tumor or even the metastases. (138) To prevent malignancy and metastasis, CSCs need to be eradicated. Due to their plasticity, this could be tricky to find a specific niche component target that relevant to particular cancer type so a standard promising cancer therapy can tackle the tumor bulk effectively. Thus, we need a better understanding of CSCs biology and niche factors of each cancer subtype, and their modulation to various therapeutic design to develop a fully applicable therapy strategy in the clinic. (122) Mechanism of Therapy Resistance in CSC CSCs have lately been identified and characterized in many types of solid tumors and may have role in treatment failure since they have been shown to be relatively resistant to conventional therapies. Recent data propose that both intrinsic and extrinsic determinants confer radioresistance to CSC through a variety of mechanisms. apparent volumetric reduction, however, is subsequently followed by local recurrence. While debate continues as to the precise identity and function of CSCs, there is common agreement that CSCs show increased chemoresistance and radioresistance. (140) (141) (142) 145 ) Therefore, understanding the biology of chemoresistance potential of CSCs may contribute to our understanding of tumor biology and would have far-reaching clinical implications.
Mechanisms of radioresistance in CSC include: CSCs display enhanced DNA repair activity, at least in part due to enhanced activation of the DNA damage checkpoint.
(1,2) CSCs contain lower reactive oxygen species (ROS) levels and overexpress ROS scavengers, resulting in less DNA damage after ionizing radiation.(3) CSCs can induce autophagy to promote survival. (4) The canonical Wnt/β-catenin signaling pathway and (5) the Notch signaling pathway are over-activated in CSCs, leading to upregulated transcription of genes responsible for cell proliferation and survival.(6) CSCs may be located in hypoxic niches within tumors which would contribute to resistance to radiation. (139) There is raising evidence that polycomb group (PcG) proteins (discovered in Drosophila as epigenetic gene silencers) play an important role in cancer development and recurrence. PcG of proteins is composed of two multimeric protein complexes, which are the polycomb repressive complex (PRC)1 and PRC2.(146) The PRC1 complex includes B cell-specific Moloney murine leukemia virus integration site 1 (BMI1), Mel-18, Mph1/Rae28, M33, sex comb on midleg homolog 1 (SCMH1) and Ring2, meanwhile the PRC2 complex includes Eed, EzH, Suz12, and YY1. (146) BMI1 is reported to play a crucial role in self-renewal of stem cells and is associated with a number of human malignancies. (141, 144, (147) (148) (149) Recent studies suggest that BMI1 is involved in the initiation of cancer, and targeting BMI1 by gene therapy abolishes chemoresistance in tumor cells. (141, 142) The inability of tumor cells to go through apoptosis in response to chemotherapy gives a selective advantage for tumor progression, metastasis, and resistance to therapy. BMI1 has been known to be associated with the protection of tumor cells from apoptosis. Cui, et al., showed that the ectopic expression of BMI1 rescues keratinocytes from stress-induced apoptosis. (148) But the precise mechanism of BMI1 on the regulation of chemoresistance in tumor cells is no fully understood. It is reported that BMI1 modulates several molecular pathways within the cells. BMI1 has been shown to induce its effect at epigenetic as well as genetic level. (146, 154, 155) It is believed that chromatin modifications induced by PcG proteins, including BMI1, form an obstacle to transcription factors and RNA polymerase binding. (155, 156) BMI1 has been reported to be associated with the progression, recurrence, and chemoresistance to the various types of cancer cells. Hence, it is of great clinical value to further understand the molecular mechanism underlying the regulation of BMI1 in CSCs and chemoresistance. This will not only help in understanding the role of BMI1 in the growth of CSCs and chemoresistance but will also provide insights for the establishment and development of new strategies and effective clinical therapies for the treatment of chemoresistant cancers. (156) Targeting CSC Therapies A growing body of studies indicates that CSCs are intrinsically more resistant to chemotherapeutic agents and radiation than the bulk of tumor cells, and thus play an important role in persistence of cancer residual disease and recurrence. This drug resistance in CSCs has been attributed to highly expressed drug efflux pumps (for example, the MDR proteins), enhanced DNA repair proteins, expression of antiapoptotic proteins, and a slow rate of cell proliferation. (157) Thus, it is important to develop effective therapeutic strategies to eliminate CSCs and overcome cancer resistance to chemotherapy and radiotherapy. (158) Conventional anticancer approaches are directed predominantly at bulk tumor populations. That kind of strategies often have limited efficacy because of the intrinsic or acquired drug resistance and/or resistance to ionizing radiation.(160) Mechanisms of therapeutic resistance include increased recognition and repair of DNA damaged by the drug or ionizing radiation, altered cell cycle checkpoint control, impaired functioning of apoptotic pathways, and reduced drug accumulation as a result of increased expression of ABC transporters which efflux drug. (160, 161) Evidence has showed that CSCs represent a subpopulation of cells within cancers that is characterized by increased resistance to chemo-and radiotherapy, indicating that conventional anticancer approaches might frequently fail to eradicate the cell subset which initiates and perpetuates tumorigenesis ( Figure 5 ).(159) For example, CSC chemoresistance has been reported in human leukemias (162) (163) (164) (165) (166) (167) (168) (169) , in malignant melanoma (169, 170) , and in brain (171) , breast (50, 172) , pancreatic (64) , and colorectal (173) cancers. Furthermore, CSC radioresistance has been identified in brain (48) and breast (51, 174) cancers. CSCs in human indeed are the major culprits for tumor development, malignant progression, and responsible for therapeutic resistance. CSCs then were a potential target for effectively treatments and reducing the tumor relapse and metastasis. (159) A number of therapeutic strategies directed at CSC are beginning to be experimentally confirmed. These approaches could potentially intensify responsiveness to current anticancer treatment regimens and might reduce the risk of relapse and dissemination. The approaches include ablation using antitumor agents which target prospective markers of CSCs (e.g., monoclonal antibodies and activated immune cells), reversal of chemo-or radio-resistance mechanisms operative in CSC, CSC pathway interference, differentiation therapy, disruption of protumorigenic CSC-microenvironment interactions, antiangiogenic or antivasculogenic therapy, and disruption of immunoevasion pathways ( Figure 6 ). (159) Monoclonal antiboy-based strategies that target molecules expressed by CSCs, for example EpCAM on breast and colon CSCs (9, 63) , are already being translated to the clinic.(48) These developments underline the therapeutic promise of the CSC concept. Ultimately, patient cures will require eradication of all cells within a cancer. So combination therapies which target both CSCs and bulk cancer populations are tend to emerge as particularly effective clinical strategies, especially in those malignancies currently refractory to conventional anticancer agents directed predominantly at the bulk tumor cell populations. (159) Recent studies have revealed that cancer immunotherapy is a possible and promising candidate to target CSCs. Among the various immunological effector cells, cytotoxic T lymphocytes (CTL) are a good candidate for CSC-targeted immunotherapy as CTLs are antigenspecific effector cells. (176) In addition, identification of specific antigens or genetic alterations in CSCs may provide more specific targets for immunotherapy. ALDH, CD44, CD133, and ErBb2 have perfomed as markers to isolate CSCs from a number of tumor types in animal models and human tumors. They might serve as useful targets for CSC immunotherapy. In the end, since CSCs are regulated by interactions with CSC niche, these interactions may serve as additional targets for CSC immunotherapy. Targeting the tumor microenvironment, such as interrupting the immune cell, for example, myeloid-derived suppressor cells, and cytokines, for example, IL-6 and IL-8, as well as the immune checkpoint (programmed cell death 1 (PD1)/programmed death-ligand 1 (PDL1), etc.) may provide additional novel strategies to enhance the immunological targeting of CSCs. (176) The growing number of reports regarding CSCs has significantly raised the complexity of our understanding of their basic and clinical biology. Some properties, such as drug resistance and migratory and invasive potential, are now attributed to CSCs in addition to their defining characteristics of tumorigenicity and self-renewal that suggests a major role in disease relapse and progression. Although these findings have served as a foundation to develop novel therapies, proof that CSCs are clinically relevant is still lacking. Improved overall survival resulting from the documented inhibition of CSCs will provide the most definitive evidence for their importance, but challenges exist in identifying the proper end-points to clinically assess therapies targeting these cells. (177) The CSC hypothesis provides an attractive cellular mechanism to account for the therapeutic refractoriness and dormant behavior exhibited by many of these tumor. But recent observations have highlighted many complexities and challenges. The CSC phenotype can vary substantially between patients, tumors may harbor multiple phenotypically or genetically distinct CSCs, metastatic CSCs can evolve from primary CSCs, and tumor cells may undergo reversible phenotypic changes. The clinical relevance of CSCs remains a fundamental issue but preliminary findings show that specific targeting may be possible.
Conclusion
